Literature DB >> 30483814

Leukocyte‑associated immunoglobulin‑like receptor 1 promotes tumorigenesis in RCC.

Kentaro Jingushi1, Motohide Uemura1, Kosuke Nakano2, Yujiro Hayashi2, Cong Wang2, Yu Ishizuya2, Yoshiyuki Yamamoto2, Takuji Hayashi2, Toshiro Kinouchi2, Kyosuke Matsuzaki2, Taigo Kato2, Atsunari Kawashima2, Takeshi Ujike2, Akira Nagahara2, Kazutoshi Fujita2, Koji Ueda3, Kazutake Tsujikawa4, Norio Nonomura2.   

Abstract

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for approximately 90‑95% of cases. We previously reported a novel method that enables direct extraction of extracellular vesicles (EVs) from surgically resected viable tissues, yielding what we term tissue‑exudative extracellular vesicles (Te‑EVs). Quantitative LC/MS analysis identified 3,871 proteins in Te‑EVs, among which leukocyte‑associated immunoglobulin‑like receptor 1 (LAIR1) was highly enriched in tumor Te‑EVs. In the present study, we found that LAIR1 was significantly upregulated in clinical specimens of human RCC tumor tissues compared to that noted in adjacent non‑cancerous renal tissues as determined by quantitative PCR analysis. LAIR1 overexpression resulted in accelerated cell proliferation and tumor growth in RCC cells. Moreover, knockdown of LAIR1 using siRNA significantly inhibited cell proliferation in RCC cells. Mechanistically, LAIR1 upregulated the phosphorylation status of Akt, which in turn increased cell proliferation in RCC cells. In clinical RCC specimens, RCC patients with high LAIR1 mRNA expression showed poor progression‑free survival compared to those with low LAIR1 expression. These findings indicate that LAIR1 promotes tumorigenesis in RCC.

Entities:  

Year:  2018        PMID: 30483814     DOI: 10.3892/or.2018.6875

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Cancer immunotherapy based on blocking immune suppression mediated by an immune modulator LAIR-1.

Authors:  Lijun Xu; Shanlong Wang; Jufeng Li; Jie Li; Bingyu Li
Journal:  Oncoimmunology       Date:  2020-04-07       Impact factor: 8.110

2.  ALKBH4 promotes tumourigenesis with a poor prognosis in non-small-cell lung cancer.

Authors:  Kentaro Jingushi; Masaya Aoki; Kazuhiro Ueda; Takahiro Kogaki; Masaya Tanimoto; Yuya Monoe; Masayuki Ando; Takuya Matsumoto; Kentaro Minami; Yuko Ueda; Kaori Kitae; Hiroaki Hase; Toshiyuki Nagata; Aya Harada-Takeda; Masatatsu Yamamoto; Kohichi Kawahara; Kazuhiro Tabata; Tatsuhiko Furukawa; Masami Sato; Kazutake Tsujikawa
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

3.  Blocking LAIR1 signaling in immune cells inhibits tumor development.

Authors:  Jingjing Xie; Xun Gui; Mi Deng; Heyu Chen; Yuanzhi Chen; Xiaoye Liu; Zhiqiang Ku; Lingxiao Tan; Ryan Huang; Yubo He; Bruce Zhang; Cheryl Lewis; Kenian Chen; Lin Xu; Jian Xu; Tao Huang; X Charlene Liao; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

4.  Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma.

Authors:  Daniel Wai-Hung Ho; Yu-Man Tsui; Lo-Kong Chan; Karen Man-Fong Sze; Xin Zhang; Jacinth Wing-Sum Cheu; Yung-Tuen Chiu; Joyce Man-Fong Lee; Albert Chi-Yan Chan; Elaine Tin-Yan Cheung; Derek Tsz-Wai Yau; Nam-Hung Chia; Irene Lai-Oi Lo; Pak-Chung Sham; Tan-To Cheung; Carmen Chak-Lui Wong; Irene Oi-Lin Ng
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

5.  Does the Urinary Proteome Reflect ccRCC Stage and Grade Progression?

Authors:  Lucia Santorelli; Martina Stella; Clizia Chinello; Giulia Capitoli; Isabella Piga; Andrew Smith; Angelica Grasso; Marco Grasso; Giorgio Bovo; Fulvio Magni
Journal:  Diagnostics (Basel)       Date:  2021-12-16

6.  Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro.

Authors:  Richard C Zieren; Liang Dong; David J Clark; Morgan D Kuczler; Kengo Horie; Leandro Ferreira Moreno; Tung-Shing M Lih; Michael Schnaubelt; Louis Vermeulen; Hui Zhang; Theo M de Reijke; Kenneth J Pienta; Sarah R Amend
Journal:  Med Oncol       Date:  2021-07-31       Impact factor: 3.064

Review 7.  Complement's favourite organelle-Mitochondria?

Authors:  Jubayer Rahman; Parul Singh; Nicolas S Merle; Nathalie Niyonzima; Claudia Kemper
Journal:  Br J Pharmacol       Date:  2020-09-28       Impact factor: 8.739

8.  A united risk model of 11 immune‑related gene pairs and clinical stage for prediction of overall survival in clear cell renal cell carcinoma patients.

Authors:  Zijia Tao; Enchong Zhang; Lei Li; Jianyi Zheng; Yiqiao Zhao; Xiaonan Chen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.